Cytokinetics(US:CYTK) Globenewswire·2025-09-26 02:27Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the timeline for the New Drug Application (NDA) submission and approval process for aficamten, potentially causing financial damages to investors [1][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Cytokinetics common stock between December 27, 2023, and May 6, 2025 [1]. - Defendants allegedly made false statements about the expected FDA approval for aficamten, claiming it would occur in the second half of 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy (REMS) [4]. Group 2: Investor Information - Investors who purchased Cytokinetics stock during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the law firm directly for more information [3][5]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3].